去甲斑蝥素联合紫杉醇对激素抵抗性前列腺癌患者的临床疗效研究  

Clinical efficacy of norcantharidin combined with paclitaxel in patients with hormone refractory prostate cancer

作　　者：宋振国 赵鹏程 王卫国 王素娟 SONG Zhenguo;ZHAO Pengcheng;WANG Weiguo;WANG Sujuan(Department of Pharmacy;Department of Urology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, He＇ nan, China)

机构地区：[1]郑州大学附属肿瘤医院药学部,郑州450008 [2]郑州大学附属肿瘤医院泌尿外科,郑州450008

出　　处：《癌症进展》2018年第6期719-721,796,共4页Oncology Progress

摘　　要：目的探讨去甲斑蝥素联合紫杉醇对激素抵抗性前列腺癌(HRPC)患者的临床疗效及安全性。方法选择90例HRPC患者,依据随机数字表法将患者分为试验组(n=45)和对照组(n=45),试验组患者接受去甲斑蝥素联合紫杉醇化疗,对照组患者接受紫杉醇单药化疗。分析比较两组患者的疗效、生存情况及不良反应发生情况。结果试验组患者的总有效率为82.2%(37/45),高于对照组的46.7%(21/45),差异有统计学意义(P﹤0.05)。试验组患者的累积生存率为44.4%,中位生存时间为21.9个月(18.5~25.3个月);对照组患者的累积生存率为28.9%,中位生存时间为18.9个月(15.9~21.9个月),组间比较差异有统计学意义(P﹤0.05)。试验组患者的好转情况明显优于对照组,差异有统计学意义(P﹤0.01)。两组患者的不良反应发生情况比较,差异无统计学意义(P﹥0.05)。结论去甲斑蝥素联合紫杉醇对HRPC患者的临床疗效显著,且安全性好。Objective To evaluate the efficacy and safety of combination treatment of norcantharidin and paclitaxel in patients with hormone refractory prostate cancer（HRPC）. Method Nighty cases of HRPC were selected and divided into experimental group（n=45） and control group（n=45） according to random digital table. The patients in the experimental group received norcantharidin and paclitaxel chemotherapy, and the control group received paclitaxel chemotherapy only. The efficacy, survival and adverse reactions of the two groups were analyzed. Result The total effective rate of experimental group was 82.2%（37/45）, which was significantly higher than that of the control group at 46.7%（21/45）, the difference was statistically significant（P〈0.05）. The cumulative survival rates of experimental group and control group were 44.4% and 28.9%, respectively; and the median survival time were 21.9（18.5-25.3） months and 18.9（15.9-21.9）months, respectively; the difference was statistically significant（P〈0.05）. The improvement of patients in experimental group was significantly better than that of patients in control group（P〈0.01）. There was no significant difference in adverse reactions between the two groups（P〉0.05）. Conclusion The regimen of norcantharidin combined with paclitaxel is effective and safe in the treatment on patients with HRPC.

关 键 词：去甲斑蝥素 紫杉醇 激素抵抗性前列腺癌 临床疗效 

分 类 号：R737.25[医药卫生—肿瘤]